Table I.
Patient Characteristics.
| Patient | Histology | Gender | Stage |
Age > 60 |
LDH (>ULN) |
CLIPI | IPI |
Prior Radiation |
Lines Prior Rx (#) |
|---|---|---|---|---|---|---|---|---|---|
| 001 | CTCL (SS) | M | IVA1 | Y | Y | hi | N/A | N | 12 |
| 002 | CTCL (SS) | f | IVA1 | Y | N | int | N/A | N | 1 |
| 003 | CTCL (SS) | M | IVA1 | Y | Y | hi | N/A | N | 1 |
| 004 | CTCL (SS) | M | IVA1 | Y | Y | hi | N/A | N | 1 |
| 005 | PTCL TFH phenotype | M | IVA | Y | N | N/A | 2 | N | 1 |
| 006 | PTCL, NOS | M | IIIA | N | N | N/A | 1 | Y | 1 |
| 007 | PTCL TFH phenotype | M | IVA | N | N | N/A | 1 | N | 3 |
| 008 | ALCL, ALK− | M | IVA | N | Y | N/A | 3 | Y | 2 |
| 009 | ALCL, ALK− | M | IVA | Y | Y | N/A | 4 | N | 3 |
| 010 | PTCL TFH phenotype | f | IVA | Y | Y | N/A | 4 | N | 1 |
| 011 | CTCL (SS) | M | IVA1 | Y | Y | hi | N/A | N | 2 |
| 012 | PTCL, NOS | f | IVA | Y | Y | N/A | 4 | Y | 1 |
| 013 | CTCL (MF) | M | IIb | Y | Y | int | N/A | Y | 2 |
Note: The CTCL International Prognostic Index (CLIPI) for patients with advanced-stage disease is comprised of 5 variables: male gender, age >60, B1/B2, N2/N3 and visceral metastases. Patients are risk-stratified into low (0–1 risk factors), intermediate (2 risk factors), or high-risk (≥3 risk factors) groups. The International Prognostic Index (IPI) was utilized for PTCL risk-stratification and the number of risk factors (age >60, elevated LDH, ECOG performance status >1, >1 extranodal site of disease, Ann Arbor Stage III/IV) reported.